Jose Vazquez

Dr. Jose Vazquez

1. Division of Infectious Diseases, Professor of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of the American Academy of Orthopaedic Surgeons
Verified
Journal Article
Closed access
MAMohamed E. Awad
Mohamed E. Awad
JRJacob C.L. Rumley
Jacob C.L. Rumley
Jose VazquezJose Vazquez
Jose Vazquez
JDJohn G. Devine
John G. Devine
By April 7, 2020, severe acute respiratory syndrome coronavirus 2 was responsible for 1,383,436 confirmed cases of Coronavirus disease 2019 (COVID-19), involving 209 countries around the world; 378,881 cases have been confirmed in the United States. During this pandemic, the urgent surgical requirements will not stop. As an example, the most recent Centers of Disease Control and Prevention reports estimate that there are 2.8 million trauma patients hospitalized in the United States. These data illustrate an increase in the likelihood of encountering urgent surgical patients with either clinically suspected or confirmed COVID-19 in the near future. Preparation for a pandemic involves considering the different levels in the hierarchy of controls and the different phases of the pandemic. Apart from the fact that this pandemic certainly involves many important health, economic, and community ramifications, it also requires several initiatives to mandate what measures are most appropriate to prepare for mitigating the occupational risks. This article provides evidence-based recommendations and measures for the appropriate personal protective equipment for different clinical and surgical activities in various settings. To reduce the occupational risk in treating suspected or confirmed COVID-19 urgent orthopaedic patients, recommended precautions and preventive actions (triage area, emergency department consultation room, induction room, operating room, and recovery room) are reviewed.

27 March 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Jose VazquezJose Vazquez
Jose Vazquez
LWLissette Whitaker
Lissette Whitaker
AZAnna Zubovskaia
Anna Zubovskaia
Invasive fungal infections in the intensive care unit (ICU) are not uncommon and most cases are caused by Candida species, specifically Candida albicans. However, recently, there has been an increase in non-albicans Candida spp. (C. glabrata; C. parapsilosis) causing invasive fungal infections. This has led to an increasing awareness of this infection due to the increase in documented antifungal resistance in many of these Candida species. In addition, manifestations of invasive candidiasis are often non-specific, and the diagnosis remains extremely challenging. Unfortunately, delays in antifungal therapy continue to hamper the morbidity; length of stay; and the mortality of these infections. Although the echinocandins are the drugs of choice in these infections, antifungal resistance among the non-albicans species (C. glabrata; C. krusei; C. auris; C. parapsilosis) is being observed more frequently. This has led to an increase in morbidity and mortality, specifically in critically ill patients. Overall, the diagnosis and management of invasive candidiasis in the ICU remain challenging. It is imperative that the critical care physician keeps this infection at the forefront of their differential diagnosis in order to decrease the mortality rate of these individuals. In this review, we discuss the current epidemiologic trends, diagnosis, and management of invasive candidiasis in the intensive care unit setting.

1 January 2016 in Pulmonary and Critical Care Medicine
Verified
Journal Article
Open access
Jose VazquezJose Vazquez
Jose Vazquez
MTMaria Paula Tovar-Torres
Maria Paula Tovar-Torres
AHAmeet Hingwe
Ameet Hingwe
FCFaiqa Cheema
Faiqa Cheema
VWVerna L Welch
Verna L Welch
KFKimbal D Ford
Kimbal D Ford
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.

27 February 2021 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
RCRhonda E Colombo
Rhonda E Colombo
Jose VazquezJose Vazquez
Jose Vazquez
: Invasive fungal infections, especially candidemia and invasive candidiasis, cause significant morbidity and mortality. The epidemiology of candida infections have changed dramatically due to an i...

17 September 2025 in Mycoses
Verified
Journal Article
Open access
IRIlana Reinhold
Ilana Reinhold
GMGiovanni Mori
Giovanni Mori
MLMassimiliano Lanzafame
Massimiliano Lanzafame
ALAlessandro Limongelli
Alessandro Limongelli
AVAntonio Vena
Antonio Vena
DSDanila Seidel
Danila Seidel
Background: Rezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real‐world experience remains limited.Methods: A retrospective analysis of patients treated with rezafungin across Germany, Italy, Spain, and the United States between January 2024 and June 2025 was conducted. Data was collected via the FungiScope registry. Clinical characteristics, indications for rezafungin, outcomes, safety, and logistical aspects of administration were evaluated.Results: Fifteen patients were included, fourteen with IC; one with chronic pulmonary aspergillosis. Regarding patients with IC, the median age was 65.5 years; 43% were female. The most frequently identified pathogens were Candida glabrata (57%) and Candida parapsilosis (21%). Primary indications for rezafungin were intravascular (36%) and osteoarticular infections (36%). Rezafungin was mainly selected to enable OPAT (86%) or due to fluconazole resistance (36%) or drug–drug interactions (14%). The median treatment duration was 9 weeks (range: 1–38 weeks). One mild adverse event occurred (cutaneous photosensitivity), but rezafungin was otherwise well tolerated. Complete clinical or mycological response was observed in 36% at day 30, and partial response in 50% of patients. Access differed substantially across centres due to administrative and reimbursement hurdles, affecting treatment transition to rezafungin in 71% of patients with IC.Conclusions: Rezafungin was effective and well tolerated in this cohort, particularly in patients requiring long‐term treatment. Administrative and logistical hurdles remain significant barriers to its widespread use. Facilitated access and enhanced awareness may improve patient outcomes by supporting early initiation and continuity of care.

23 April 2021 in Gastroenterology Clinics of North America
Verified
Journal Article
Closed access
ACAndrew Chao
Andrew Chao
Jose VazquezJose Vazquez
Jose Vazquez